DocGo’s Leap of Faith: Hicuity Acquisition and a Pivot to Virtual Care
Micro-cap DocGo bets on a transformative acquisition and new financing to offset wider losses and a shrinking balance sheet.
DCGO · Earnings Call · 2026-08-17
A Transformational Bet on Virtual Care
DocGo Inc. (DCGO) reported its Q2 2026 earnings on August 17, and the call was dominated not by the numbers—which showed revenue down 21% year-over-year—but by the announcement of a definitive agreement to acquire Hicuity Health, a leader in acute and critical care telemedicine. The move is a dramatic attempt to reshape a company that has been in freefall: its stock has lost 95.8% of its value since its 2022 peak, and the latest 90-day trend shows a 41% drawdown from an already-depressed April high.
The second quarter was a transformational period for our company, and the recent weeks marked a number of key milestones.
CEO Lee Bienstock framed the acquisition as the centerpiece of a broader strategy to "match the right clinician with the right patient at the right time in the right setting." The deal brings in a $65 million-trailing-revenue business with 400+ clinical staff, and—crucially—$52 million in assumed debt from Perceptive Advisors, along with a commitment for up to $50 million in additional financing. This is not just a bolt-on; it is a financial lifeline for a company whose total revenue has collapsed from $186 million in Q2 2024 to $76 million in the latest quarter.
The acquisition also extends DocGo's reach into Health systems, a segment where it already has "entrenched relationships" on the medical transportation side, but where virtual care and in-home services create new cross-selling opportunities. As Lee noted, "there is a nice opportunity for us to provide additional in-person care services in the home, like mobile phlebotomy and other preventative care and transitional care services." The company's own keyword trajectory for 20263 reflects this pivot, with transitional care management, virtual care, and clinical practice among the top movers—terms that were absent from prior quarters focused on SteadyMD weight loss or migrant-related projects.
Cost Cuts and AI Efficiency vs. Guidance Reality
While the acquisition story is forward-looking, the company's near-term financials remain strained. Total revenue for Q2 was $73.4 million, down from $80.4 million a year ago, but non-migrant revenue grew 19%, and organic growth—excluding both migrant and SteadyMD—was roughly 5%, per CFO Norm Rosenberg. Yet the adjusted EBITDA loss widened to $6.3 million, and management cut full-year guidance to a $17–$22 million loss, much worse than the prior $5–$10 million range.
“By organic, what we're doing is we're looking at business lines that existed both in Q2 of 2025 and Q2 of 2026... that number was roughly 5% year-over-year.” — Norm Rosenberg, Chief Financial Officer · 2026-08-17
The company is leaning on cost-cutting and AI efficiency programs to bridge the gap. In the prepared remarks, Lee highlighted an AI communications tool that handles 60% of inbound patient calls and 100% of outbound scheduling, processing over 1,000 calls a day without human intervention. He also noted 65% of orders now flow through AI data entry, with a target of 90% by year-end, cutting per-order processing costs from $2 to "mere pennies." These initiatives are part of a broader push that management estimates could yield $6 million in annual savings.
This efficiency narrative echoes prior quarters. In the May 2026 call, Norm had already warned about cost lag: “part of the reason why we saw higher expenses than we would have expected in Q1 is typically, what will happen is we will swap out one vendor for another vendor. That's lower priced or we will just stop working with a vendor.” — Norman Rosenberg, Management (likely CFO) · 2026-05-12 Now, with a substantial reduction in force during Q2, the company is starting to see those savings flow through, but the impact has been slower than hoped.
Regulatory and Operational Risks
The acquisition also brings new risks. On the call, an analyst raised concerns about potential CMS cuts to remote patient monitoring (RPM) reimbursement for 2027. Lee pushed back, arguing that DocGo's model focuses on chronic care management rather than mere monitoring: "But managing patients and their chronic conditions, I think over time is going to get rewarded more and more, and that is exactly what we do." He noted that the vast majority of the ~55,000 monitored patients are cardiac device patients, a category not under discussion, while only ~2,000 are in the more vulnerable RPM category.
Fuel costs also remain a drag on transport margins—per-gallon prices rose to $4.27 from $3.16 a year ago, costing roughly 60 basis points of transport gross margin. And the balance sheet shows effective net cash shrinking from a peak of $207 million to $47 million as losses mount.
The company is also facing a long-delayed payment from New York City's HPD (migrant-related receivables), with ~$13 million still outstanding. Management says collection timing remains unpredictable.
Looking Ahead
DocGo's stock has been beaten down to a level where the market cap is about $60 million, roughly equal to the $52 million debt being assumed. The acquisition is a bold attempt to create a scaled, unified mobile and virtual care platform, but execution risk is high. The company must integrate Hicuity, realize synergies, and navigate a tightening reimbursement environment—all while managing a still-negative EBITDA trajectory.
“So in terms of migrant-related revenues for 2026, we don't expect any migrant-related revenues for 2026.” — Lee Bienstock, Chief Executive Officer · 2025-11-10
That prior call from November 2025 set the stage for a business built on organic growth, but the latest guidance suggests that transition is proving harder than expected. The next few quarters will be critical in determining whether DocGo's leap of faith lands or leaves it further adrift.